Goal-based evidence guide
Peptides for muscle growth: what the evidence actually shows
This is one of the most-searched peptide questions on the internet, and one of the worst answered. Here is the honest version: which compounds people mean, what has genuinely been tested in humans, and where the marketing runs past the data.
The short answer
The compounds people are usually asking about
Seven profiles cover almost everything marketed under 'muscle growth peptides'. Each links to a full evidence record.
CJC-1295
A long-acting GHRH analogue abandoned after early human studies — it reliably raises growth hormone, but the outcomes it is sold for were never tested.
Ipamorelin
A selective growth hormone secretagogue discontinued after its trials missed their endpoints — now sold for physique and recovery claims no trial ever tested.
Evidence is mostly preclinical
GHRP-2
One of the original growth-hormone secretagogue peptides — real pharmacology, no approved physique indication, and formal FDA compounding safety concerns.
Evidence is mostly preclinical
GHRP-6
The older sibling of GHRP-2, with historical human pharmacology but no approved indication and a notable appetite-stimulating effect.
Evidence is mostly preclinical
Tesamorelin
An approved medicine for one specific indication, routinely marketed for a much broader one.
BPC-157
The internet's favourite healing peptide: a mountain of rodent data and almost no controlled human evidence.
Evidence is mostly preclinical
TB-500 / Thymosin beta-4
A genuine biological protein with real research history, and a separate online product that is not quite the same thing.
Evidence is mostly preclinical
Family 1: growth-hormone secretagogues
CJC-1295, ipamorelin, GHRP-2 and GHRP-6 — the core of most 'muscle growth' stacks.
What is established
- These compounds genuinely stimulate growth-hormone release; early human pharmacology studies confirmed GH and IGF-1 elevation.
- That is the entire proven story: a hormonal effect, measured in blood, over hours to days.
- Raising a hormone is a surrogate endpoint — it only matters if it translates into a clinical outcome, and that translation was never tested.
What was never established
- No controlled trial shows meaningful muscle gain, fat loss or performance improvement in healthy adults from any of these compounds.
- CJC-1295's development stopped after early human studies; ipamorelin's programme was discontinued after trials missed their endpoints in a different indication.
- Water retention and scale-weight changes from GH elevation are routinely mistaken for tissue gain in before-and-after marketing.
Regulatory reality
Family 2: the 'healing' peptides sold as muscle builders
BPC-157 and TB-500 are usually framed as recovery accelerators that let you train harder — a muscle-growth claim by proxy.
The preclinical literature here is genuinely large — mostly rodent injury models reporting faster tendon, muscle and wound healing. The human literature is close to empty. No adequately powered, published, randomised controlled trial supports musculoskeletal healing in humans for either compound, and “TB-500” as sold online is typically a synthetic fragment that is not interchangeable with the thymosin beta-4 studied clinically.
Even taken at face value, these are recovery claims, not growth claims — and recovery claims are themselves unproven in humans. The FDA has placed BPC-157 and thymosin beta-4 fragments on the 503A Category 2 list of bulk substances presenting significant safety risks for compounding, which is a regulatory safety concern, not a verdict that any individual was harmed.
The one approved growth-hormone-axis medicine
Tesamorelin is the exception that proves the rule.
Tesamorelin is a GHRH analogue with real randomised, placebo-controlled evidence — for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy. That is a specific, labelled indication in a specific population. Its label states it is not indicated for weight-loss management, it is not approved for body recomposition or muscle building in healthy adults, and even within its indication the benefit reverses after stopping.
It is the strongest evidence on this page, and it still does not support the claim this page is about. That contrast is the whole lesson: when a peptide genuinely works for something, a regulator can say exactly what, in whom, and on which evidence.
Are peptides safe for muscle growth?
Two separate risks that marketing deliberately merges into one.
The molecule
Chronic growth-hormone and IGF-1 elevation has unresolved long-term safety questions, including a theoretical mechanistic concern around cell proliferation. For most compounds on this page, no systematic human safety dataset exists at all — absence of reported harm is not evidence of safety.
The supply chain
Unapproved supply chains have documented problems with purity, sterility, mislabelling and dose accuracy — frequently the bigger risk of the two. We do not link to or evaluate sellers, and a seller’s certificate of analysis is not independent verification.
Related claim checks
The specific claims behind this page, graded individually in the Claim Checker.
“BPC-157 heals tendons in humans.”
Unsupported as stated — the human trials simply don't exist.
“Peptides that raise growth hormone will build muscle in healthy adults.”
Unsupported as stated — raising a hormone is a surrogate endpoint, not a result.
“TB-500 and thymosin beta-4 are the same thing.”
Partly supported — related, but not interchangeable, and marketing blurs it deliberately.
What would change this picture
- A published, adequately powered randomised controlled trial measuring muscle or functional outcomes — not hormone levels — in healthy adults.
- Independent replication of the core preclinical findings outside the small research networks that produced them.
- Any systematic human safety and pharmacokinetic dataset for the compounds as actually sold.
- A regulatory approval for a body-composition indication, which would come with exactly the trial evidence currently missing.
Until one of those happens, the honest grade stays where it is — and if it changes, the Evidence Update Log will record it.
Educational information only